Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients

Molecular Vision

Volumn 15, Issue , 2009, Pages 1673-1679

  Rosen, Richard ^a,b   Hu, Dan Ning ^a,b   Perez, Violete ^a   Tai, Katy ^a   Yu, Guo Pei ^a,b   Chen, Min ^a,b   Tone, Paul ^c   McCormick, Steven A ^a,b   Walsh, Joseph ^a,b  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c RICHMOND UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; CREATININE; MELATONIN;

AGE DISTRIBUTION; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE URINE LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; SEX DIFFERENCE; URINALYSIS;

AGED; AGING; CASE-CONTROL STUDIES; CREATININE; DEMOGRAPHY; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MELATONIN;

EID: 69249213707     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72:2183-98.
2. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006; 41:297-305.
3. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60:97-108.
4. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006; 273:2813-38.
5. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000; 7:444-58.
6. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
7. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50:1129-46.
8. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34:237-56.
9. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-97.
10. Reiter RJ, Tan DX, Manchester LC, Lopez-Burillo S, Sainz RM, Mayo JC. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol 2003; 527:539-48.
11. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54:1-9.
12. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
13. Radogna F, Paternoster L, Albertini MC, Cerella C, Accorsi A, Bucchini A, Spadoni G, Diamantini G, Tarzia G, De Nicola M, D'Alessio M, Ghibelli L. Melatonin antagonizes apoptosis via receptor interaction in U937 monocytic cells. J Pineal Res 2007; 43:154-62.
14. Esposito E, Iacono A, Muià C, Crisafulli C, Mattace Raso G, Bramanti P, Meli R, Cuzzocrea S. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J Pineal Res 2008; 44:78-87.
15. Molpeceres V, Mauriz JL, García-Mediavilla MV, González P, Barrio JP, González-Gallego J. Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. J Gerontol A Biol Sci Med Sci 2007; 62:687-95.
16. Koh PO. Melatonin attenuates the cerebral ischemic injury via the MEK/ ERK/p90RSK/bad signaling cascade. J Vet Med Sci 2008; 70:1219-23.
17. Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004; 37:55-70.
18. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernández C, Soria-Valles C, De Gonzalo-Calvo D, Tolivia D, Pallás M, Camins A, Rodríguez-Colunga MJ, Coto-Montes A. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. J Pineal Res 2009; 46:106-14.
19. Das A, Belagodu A, Reiter RJ, Ray SK, Banik NL. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 2008; 45:117-24.
20. Chetsawang B, Chetsawang J, Govitrapong P. Protection against cell death and sustained tyrosine hydroxylase phosphorylation in hydrogen peroxide- and MPP-treated human neuroblastoma cells with melatonin. J Pineal Res 2009; 46:36-42.
21. Montilla P, Cruz A, Padillo FJ, Túnez I, Gascon F, Muñoz MC, Gómez M, Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res 2001; 31:138-44.
22. Venkataraman P, Krishnamoorthy G, Vengatesh G, Srinivasan N, Aruldhas MM, Arunakaran J. Protective role of melatonin on PCB (Aroclor 1,254) induced oxidative stress and changes in acetylcholine esterase and membrane bound ATPases in cerebellum, cerebral cortex and hippocampus of adult rat brain. Int J Dev Neurosci 2008; 26:585-91.
23. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumorsize. J Pineal Res 1997; 23:53-8.
24. Schernhammer ES, Kroenke CH, Dowsett M, Folkerd E, Hankinson SE. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res 2006; 40:116-24.
25. Sewerynek E. Melatonin and the cardiovascular system. Neuroendocrinol Lett 2002; 23:79-83.
26. Reiter RJ. The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp Gerontol 1995; 30:199-212.
27. Sakotnik A, Liebmann PM, Stoschitzky K, Lercher P, Schauenstein K, Klein W, Eber B. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20:1314-7.
28. Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P. Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol Int 2001; 18:513-24.
29. Girotti L, Lago M, Ianovsky O, Carbajales J, Elizari MV, Brusco LI, Cardinali DP. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 2000; 29:138-42.
30. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005; 97:1084-7.
31. Kennaway DJ, Lushington K, Dawson D, Lack L, van den Heuvel C, Rogers N. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 1999; 27:210-20.
32. Hogg R, Chakravarthy U. AMD and micronutrient antioxidants. Curr Eye Res 2004; 29:387-401.
33. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999; 5:32.
34. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45:115-34.
35. Ahmed SS, Lott MN, Marcus DM. The macular xanthophylls. Surv Ophthalmol 2005; 50:183-93.
36. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417-36.
37. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75:216-30.
38. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294:3101-7.
39. Nowak M, Swietochowska E, Wielkoszyński T, Marek B, Karpe J, Górski J, Głogowska-Szelag J, Kos-Kudła B, Ostrowska Z. Changes in blood antioxidants and several lipid peroxidation products in women with age-related macular degeneration. Eur J Ophthalmol 2003; 13:281-6.
40. Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E, Saraymen R, Ustdal M. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006; 220:12-6.
41. Prashar S, Pandav SS, Gupta A, Nath R. Antioxidant enzymes in RBCs as a biological index of age related macular degeneration. Acta Ophthalmol (Copenh) 1993; 71:214-8.
42. Cohen SM, Olin KL, Feuer WJ, Hjelmeland L, Keen CL, Morse LS. Low glutathione reductase and peroxidase activity in age-related macular degeneration. Br J Ophthalmol 1994; 78:791-4.
43. Evereklioglu C, Er H, Doganay S, Cekmen M, Turkoz Y, Otlu B, Ozerol E. Nitric oxide and lipid peroxidation are increased and associated with decreased antioxidant enzyme activities in patients with age-related macular degeneration. Doc Ophthalmol 2003; 106:129-36.
44. Frank RN, Amin RH, Puklin JE. Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am J Ophthalmol 1999; 127:694-709.
45. Decanini A, Nordgaard CL, Feng X, Ferrington DA, Olsen TW. Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol 2007; 143:607-15.
46. Pardue HL, Bacon BL, Nevius MG, Skoug JW. Kinetic study of the Jaffé reaction for quantifying creatinine in serum:1. Alkalinity controlled with NaOH. Clin Chem 1987; 33:278-85.
47. Bowers LD. Kinetic serum creatinine assays I. The role of various factors in determining specificity. Clin Chem 1980; 26:551-4.
48. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998; 24:230-8.
49. Pääkkönen T, Mäkinen TM, Leppäluoto J, Vakkuri O, Rintamäki H, Palinkas LA, Hassi J. Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J Pineal Res 2006; 40:110-5.
50. Bojkowski CJ, Arendt J, Shih MC, Markey SP. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem 1987; 33:1343-8.
51. Benloucif S, Burgess HJ, Klerman EB, Lewy AJ, Middleton B, Murphy PJ. Measuring melatonin in humans. J Clin Sleep Med 2008; 4:66-9.
52. Klante G, Brinschwitz T, Secci K, Wollnik F, Steinlechner S. Creatinine is an appropriate reference for urinary sulphatoxymelatonin of laboratory animals and humans. J Pineal Res 1997; 23:191-7.
53. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol (Oxf) 1987; 27:445-52.
54. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60:1166-73.
55. Markey SP, Higa S, Shih M, Danforth DN, Tamarkin L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta 1985; 150:221-5.
56. Gögenur I, Middleton B, Kristiansen VB, Skene DJ, Rosenberg J. Disturbances in melatonin and core body temperature circadian rhythms after minimal invasive surgery. Acta Anaesthesiol Scand 2007; 51:1099-106.
57. Nagata C, Nagao Y, Shibuya C, Kashiki Y, Shimizu H. Association of vegetable intake with urinary 6-sulfatoxymelatonin level. Cancer Epidemiol Biomarkers Prev 2005; 14:1333-5.
58. Wood AW, Loughran SP, Stough C. Does evening exposure to mobile phone radiation affect subsequent melatonin production? Int J Radiat Biol 2006; 82:69-76.
59. Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacol Ther 2007; 113:507-22.
60. Tosini G, Fukuhara C. Photic and circadian regulation of retinal melatonin in mammals. J Neuroendocrinol 2003; 15:364-9.
61. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78:687-721.
62. Chiquet C, Claustrat B, Thuret G, Brun J, Cooper HM, Denis P. Melatonin concentrations in aqueous humor of glaucoma patients. Am J Ophthalmol 2006; 142:325-7.
63. Chanut E, Nguyen-Legros J, Versaux-Botteri C, Trouvin JH, Launay JM. Determination of melatonin in rat pineal, plasma and retina by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1998; 709:11-8.
64. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab 1992; 75:127-34.
65. Kannan R, Zhang N, Sreekumar PG, Spee CK, Rodriguez A, Barron E, Hinton DR. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis 2006; 12:1649-59.
66. Marin-Castaño ME, Csaky KG, Cousins SW. Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci 2005; 46:3331-40.
67. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol 1999; 117:329-39.
68. Rakoczy PE, Zhang D, Robertson T, Barnett NL, Papadimitriou J, Constable IJ, Lai CM. Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model. Am J Pathol 2002; 161:1515-24.
69. Samiec PS, Drews-Botsch C, Flagg EW, Kurtz JC, Sternberg P Jr, Reed RL, Jones DP. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic Biol Med 1998; 24:699-704.
70. Coral K, Raman R, Rathi S, Rajesh M, Sulochana KN, Angayarkanni N, Paul PG, Ramakrishnan S. Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. Eye 2006; 20:203-7.
71. Ianǎş O, Manda D, Câmpean D, Ionescu M, Soare G. Effects of melatonin and its relation to the hypothalamic-hypophyseal-gonadal axis. Adv Exp Med Biol 1999; 460:321-8.
72. Tan DX, Manchester LC, Reiter RJ, Qi WB, Karbownik M, Calvo JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9:137-59.
73. Siu AW, Reiter RJ, To CH. The efficacy of vitamin E and melatonin as antioxidants against lipid peroxidation in rat retinal homogenates. J Pineal Res 1998; 24:239-44.
74. Marchiafava PL, Longoni B. Melatonin as an antioxidant in retinal photoreceptors. J Pineal Res 1999; 26:184-9.
75. Liang FQ, Green L, Wang C, Alssadi R, Godley BF. Melatonin protects human retinal pigment epithelial (RPE) cells against oxidative stress. Exp Eye Res 2004; 78:1069-75.
76. Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of melatonin in age-related macular degeneration. Ann N Y Acad Sci 2005; 1057:384-92.
77. Wiechmann AF, Chignell CF, Roberts JE. Influence of dietary melatonin on photoreceptor survival in the rat retina: an ocular toxicity study. Exp Eye Res 2008; 86:241-50.